Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals

European Journal of Immunology

Volumn 37, Issue 5, 2007, Pages 1224-1232

  Song, Aihua ^a   Song, Jianxun ^a   Tang, Xiaohong ^a   Croft, Michael ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

CD4 help; CD8 T cells; OX40; Survival; Tumor immunity

Indexed keywords

CD134 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL DEPLETION; TUMOR IMMUNITY; WILD TYPE;

ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COOPERATION; MICE; MICE, TRANSGENIC; NEOPLASMS; OX40 LIGAND;

EID: 34250358993     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200636957     Document Type: Article

References (46)

1. Gramaglia, I., Jember, A., Pippig, S. D., Weinberg, A. D., Killeen, N. and Croft, M., The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 2000. 165: 3043-3050.
2. Gramaglia, I., Weinberg, A. D., Lemon, M. and Croft, M., Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 1998. 161: 6510-6517.
3. Rogers, P. R., Song, J., Gramaglia, L, Killeen, N. and Croft, M., OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001. 15: 445-455.
4. Song, J., So, T., Cheng, M., Tang, X. and Croft, M., Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 2005. 22: 621-631.
5. Bansal-Pakala, P., Gebre-Hiwot Jember, A. and Croft, M., Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 2001. 7: 907-912.
6. Sugamura, K., Ishii, N. and Weinberg, A. D., Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev. Immunol. 2004. 4: 420-431.
7. Vetto, J. T., Lum, S., Morris, A., Sicotte, M., Davis, J., Lemon, M. and Weinberg, A. D., Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am. J. Surg. 1997. 174: 258-265.
8. Ramstad, T., Lawnicki, L., Vetto, J. and Weinberg, A., Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am. J. Surg. 2000. 179: 400-406.
9. Petty, J. K., He, K., Corless, C. L., Vetto, J. T. and Weinberg, A. D., Survival in human colorectal cancer correlates with expression of the T- cell costimulatory molecule OX-40 (CD134). Am. J. Surg. 2002. 183: 512-518.
10. Weinberg, A. D., Rivera, M. M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J. et al., Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 2000. 164: 2160-2169.
11. Kjaergaard, J., Tanaka, J., Kim, J. A., Rothchild, K., Weinberg, A. and Shu, S., Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000. 60: 5514-5521.
12. Kjaergaard, J., Peng, L., Cohen, P. A., Drazba, J. A., Weinberg, A. D. and Shu, S., Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 2001. 167: 6669-6677.
13. Pan, P., Zang, Y., Weber, K., Meseck, M. and Chen, S., OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 2002. 6: 528-536.
14. Bansal-Pakala, P., Halteman, B. S., Cheng, M. H. and Croft, M., Costimulation of CD8 T cell responses by OX40. J. Immunol. 2004. 172: 4821-4825.
15. Cuadros, C., Dominguez, A. L., Lollini, P. L., Croft, M., Mittler, R. S., Borgstrom, P. and Lustgarten, J., Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her2/neu transgenic mice. Int. J. Cancer 2005. 116: 934-943.
16. Andarini, S., Kikuchi, T., Nukiwa, M., Pradono, P., Suzuki, T., Ohkouchi, S., Inoue, A. et al., Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 2004. 64: 3281-3287
17. Dannull, J., Nair, S., Su, Z., Boczkowski, D., Debeck, C., Yang, B., Gilboa, E. and Vieweg, J., Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 2004. 105: 3206-3213.
18. Lee, S. W., Park, Y., Song, A., Cheroutre, H., Kwon, B. S. and Croft, M., Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J. Immunol. 2006. 177: 4464-4472.
19. Rosenberg, S. A., Yang, J. C. and Restifo, N. P., Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004. 10: 909-915.
20. Rosenberg, S. A. and Dudley, M. E., Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 2004. 101 Suppl 2: 14639-14645.
21. Robbins, P. F., Dudley, M. E., Wunderlich, J., El-Gamil, M., Li, Y. F., Zhou, J., Huang, J. et al., Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 2004. 173: 7125-7130.
22. Helmich, B. K. and Dutton, R. W., The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tcl and Tc2 effectors. J. Immunol. 2001. 166: 6500-6508.
23. Ke, Y., Kapp, L. M. and Kapp, J. A., Inhibition of tumor rejection by gammadelta T cells and IL-10. Cell. Immunol. 2003. 221: 107-114.
24. Kontani, K., Kajino, K., Huangi, C. L., Fujino, S., Taguchi, O., Yamauchi, A., Yokomise, H. and Ogasawara, K., Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-beta II receptor without active antigen-sensitization. Cancer Immunol. Immunother. 2006. 55: 579-587.
25. Maeda, H., Kuwahara, H., lchimura, Y., Ohtsuki, M., Kurakata, S. and Shiraishi, A., TGF-beta enhances macrophage ability to produce IL-10 in normal and tumor-bearing mice. J. Immunol. 1995. 155: 4926-4932.
26. Porgador, A., Snyder, D. and Gilboa, E., Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 1996. 156: 2918-2926.
27. + T cell- and IL-2-dependent mechanism. Immunity 1999. 11: 483-493.
28. Zhou, F., Rouse, B. T. and Huang, L., Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study. Cancer Res. 1992. 52: 6287-6291.
29. Song, A., Tang, X., Harms, K. M. and Croft, M., OX40 and Bcl-xL promote the persistence of CD8 Tcells to recall tumor-associated antigen. J. Immunol. 2005. 175: 3534-3541.
30. Shrikant, P. and Mescher, M. F., Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J. Immunol. 2002. 169: 1753-1759.
31. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005. 105: 241-250.
32. Finkelstein, S. E., Heimann, D. M., Klebanoff, C. A., Antony, P. A., Gattinoni, L., Hinrichs, C. S., Hwang, L. N. et al., Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. J. Leukoc. Biol. 2004. 76: 333-337.
33. + effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J. Immunol. 2000. 164: 916-925.
34. Buller, R. M., Holmes, K. L., Hugin, A., Frederickson, T. N. and Morse, H. C. 3rd, Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature 1987. 328: 77-79.
35. Franco, A., Tilly, D. A., Gramaglia, L, Croft, M., Cipolla, L., Meldal, M. and Grey, H. M., Epitope affinity for MHC class I determines helper requirement for CTL priming. Nat. Immunol. 2000. 1: 145-150.
36. + T lymphocytes. Nature 2003. 421: 852-856.
37. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005. 174: 2591-2601.
38. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J. Immunol. 2000. 164: 3902-3912.
39. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 2000. 165: 6047-6055.
40. + T cell deletion induced by cross- presentation of self-antigens and favors autoimmunity. J. Exp. Med. 1997. 186: 2057-2062.
41. Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. L, Schumacher, T. N., Melief, C. J., Offringa, R. and Toes, R. E., CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 1999. 5: 774-779.
42. French, R. R., Chan, H. T., Tutt, A. L. and Glennie, M. J., CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 1999. 5: 548-553.
43. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 1999. 5: 780-787.
44. Taraban, V. Y., Rowley, T. F. and Al-Shamkhani, A., Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J. Immunol. 2004. 173: 6542-6546.
45. + T cell responses in the absence of CD4+ T cells. J. Immunol. 2005. 174: 710-717.
46. + T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC. J. Immunol. 2000. 165: 6731-6737.